Targeted therapies for obesity and insulin resistance (IR) have been speculated based on outcomes of silencing GATA3 via specific DNAzyme, which induces adipogenesis in 3T3-L1 mouse pre-adipocytes [19]. This evidence concerns the gene GATA3 and obesity disorder.